Mentis Cura - ADHD:GAD

Katla Index is an innovative (PCT/US2019/052468) cloud-based software platform that will provide an easy to use and cost-effective ADHD diagnostic and a prognostic tool that is non-invasive, accurate, reliable, and easy to interpret. The software analyses EEGs, non-invasive, inexpensive technique and widely available, from our database of EEG recordings from children aged 1-17 years (1,200) and adults (700) suffering from a variety of neurological disorders and, in combination with AI algorithms, provides a reliable ADHD diagnosis and anxiety distinction. Within a few minutes KATLA analyses and compares the data delivering a report directly to the clinician which provides not only an objective assessment of ADHD but also a gauge correlating with the effect of treatment. Katla will help clinicians and caregivers to understand the features of ADHD for an early diagnosis and intervention as well as for disease progression, patient stratification and treatment guidance. ADHD is the most common developmental disorder in school-age children. Often undetected or misunderstood, it can have a huge impact on children, their families and the wider community. Katla will help clinicians, patients and caregivers to understand features of ADHD evident in an EEG recording. In doing so, it will be an objective marker that enhances the accuracy of ADHD diagnosis, thereby providing added reassurance for everyone involved. The objective nature of Katla allows for precise optimisation of treatment options prescribed by clinicians. The technology will also have application in clinical trials for drug development. The funding (EIC Accelerator) is required to fulfil the clinical and engineering development programs, complete validation work, and initial commercialisation work including market research and KOL engagement. To develop this innovative novel technology requires high-risk funding that the company with the capital seed has been unable to secure through other funding bodies.